Publications

2020
Daniel Richard, Zun Liu, Jiaxue Cao, Ata M Kiapour, Jessica Willen, Siddharth Yarlagadda, Evelyn Jagoda, Vijaya B Kolachalama, Jakob T Sieker, Gary H Chang, Pushpanathan Muthuirulan, Mariel Young, Anand Masson, Johannes Konrad, Shayan Hosseinzadeh, David E Maridas, Vicki Rosen, Roman Krawetz, Neil Roach, and Terence D Capellini. 3/26/2020. “Evolutionary Selection and Constraint on Human Knee Chondrocyte Regulation Impacts Osteoarthritis Risk.” Cell. Publisher's Version
Pushpanathan Muthuirulan. 1/1/2020. “Genomic assays: on the brink of revolutionising human healthcare.” Drug Target Review 7 (1 ). Publisher's Version
2019
Pushpanathan Muthuirulan. 12/2019. “CRISPR: kick-starting the revolution in drug discovery.” Drug Target Review 4, Pp. 19-22. Publisher's Version
Pushpanathan Muthirulan. 9/2019. “Genomic medicine: cracking genomes to cure ‘incurable’ diseases.” Drug Target Review, no. 3, Pp. 32-34. Publisher's Version
Pushpanathan Muthuirulan. 8/1/2019. “Complex Phenotypes: Mechanisms Underlying Variation in Human Stature.” Current Osteoporosis Reports, Pp. 1-23. Publisher's Version
Pushpanathan Muthuirulan. 6/1/2019. “Personal genomics: the fast track to “precision medicine”.” Drug Target Review, no. 2, Pp. 5.
Pushpanathan Muthuirulan. 4/1/2019. “Functional Medicine: A Holistic Treatment Approach to the Peaceful Healing Journey.” Journal of Health and Human Experience, 5, 1, Pp. 50-58. Publisher's Version
Pushpanathan Muthuirulan. 3/18/2019. “Realising the promise of laboratory automation in biomedical research.” Drug Target Review, no. 1, Pp. 30-32. Publisher's Version
2018
Pushpanathan Muthuirulan. 12/7/2018. “Omics-informed drug target discovery in combating emerging infectious diseases .” Drug Target Review, no. 4, Pp. 50-52. Publisher's VersionAbstract
The catastrophic consequences of ever-increasing rates of death from infectious diseases demands new experimental strategies for drug target selection and drug design. Over the last decade, the pharmaceutical industry has been wounded by several issues including failure of drug-development programmes, burgeoning cost of drug development, increasing regulatory control, lack of innovation and declining productivity of therapeutic drugs in the market.
Pushpanathan Muthuirulan. 9/7/2018. “The changing face in drug discovery .” Drug Target Review, no. 3, Pp. 5. Publisher's Version
Pushpanathan Muthuirulan. 9/4/2018. “Next-Generation Sequencing: Hunting mysterious ‘Dark Matter Genome’ towards rewriting the rules of human genetic diseases.” Drug Target Review, no. 3, Pp. 72-75. Publisher's Version
Pushpanathan Muthuirulan. 7/2018. “‘Hurting Antibiotics’ - A Cautionary Tale to Save Human Lives.” Clinical Infectious Diseases: Open Access, 2, 2. Publisher's Version
Pushpanathan Muthuirulan. 6/1/2018. “Promising Targets for Prospective Antibacterial Therapy .” EC Microbiology, 14, 6, Pp. 351-360. Publisher's Version
Pushpanathan Muthuirulan. 5/1/2018. “Unexpected Role of Nitric Oxide Signals in Myometrial Relaxation: A Promising Therapeutic Approach in Preterm Birth Prevention .” Journal of Postdoctoral Research, 6, 5. Publisher's Version
Pushpanathan Muthuirulan. 3/2018. “Lab automation and robotics – accelerating the pace of antimicrobial therapy.” Drug Target Review 1 (1), Pp. 6-8. Publisher's Version
Pushpanathan Muthuirulan and Vaishnavi Gururajan. 1/4/2018. “CRISPR Inspires New Hope to Disease Sufferers.” Journal of Molecular Microbiology, 2, 1, Pp. 2. Publisher's Version
Pushpanathan Muthuirulan. 1/2018. “Do Microbes Care About Human Heart.” J Infect Dis Immune Ther , 2, 1. Publisher's Version
2017
Pushpanathan Muthuirulan. 12/2017. “CRISPR-Cas9: Promising Platform for Prospective Antimicrobial Therapy.” Advance Techniques in Clinical Microbiology, 1, 1. Publisher's Version
Pushpanathan Muthuirulan. 9/1/2017. “Flow Cytometry: Accelerating Neuroscience Research.” Drug Target Review, no. 3. Publisher's VersionAbstract

Flow cytometry continue to evolve at a fast pace and provides neuroscientists the capability for performing many of highly-specialized assays simultaneously. Flow cytometry meet the demands of cutting edge research in neuroscience that has allowed researchers to isolate particular neural cells from heterogeneous population and catalog its molecular or physical features. With the development of greater throughput and sensitivity, flow cytometry has become the unique tools for characterizing surface or internal antigen expression of neural cells, rapid sorting of activated neurons, assessment of neurochemical components, understanding neural morphology and cell density changes during pathophysiology of neurological disorders. The continuous expansion of flow cytometric techniques to assess the intracellular changes within neural cells such as calcium influx, cellular reactive oxygens species generation and activation of apoptosis are moving this technology into the arena of studying brain disorders. All these approaches are expanding the utility of flow cytometry as a valuable tool for neurological examination to assess the impact of neurological damage towards developing novel therapeutics to treat neurological disorder.

Pushpanathan Muthuirulan. 9/1/2017. “NGS: Empowering Infectious Disease Research Beyond Reality.” Drug Target Review, no. 3. Publisher's VersionAbstract
Translating the power of high-throughput Next-Generation Sequencing (NGS) technologies from bench to clinic is the major center of interest for many health-care providers, clinicians and researchers. NGS technologies has been used increasingly to solve many of biological problems ranging from infectious diseases to the most common and rare genetic disorders. This massively parallel sequencing technologies are revolutionizing our current ability to characterize infectious diseases at genomics, transcriptomic and epigenetics levels. NGS technology can be used to describe microbiome in health and diseases states. It has allowed identification of virulence genes for pathogenicity, gained insights into genetic difference among related pathogens, enabled development of diagnosis tools for discrimination among specific strains, revealed mechanisms of host resistance, and also provided comprehensive understanding of host-microbe interactions in infectious disease progression. Thus, NGS technologies have expanded at an unprecedented pace that led to new opportunities for prediction of potential spread of infectious agents that would allow better prognoses, diagnosis and treatment of infectious diseases. This article discusses the potential benefits and current challenges of using NGS in infectious disease diagnosis that would allow most appropriate and effective treatment of infectious diseases.

Pages